GleamWall
中文EN

ONC BeOne Medicines Ltd.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1651308 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY32.9%
TTM net income YoY1,235.6%
TTM EPS YoY1,400.0%
Revenue 3-yr CAGR44.2%
Net income 3-yr CAGR—

Margins

Gross margin89.4%
Operating margin17.8%
Net margin13.9%
FCF margin21.9%
EBITDA margin20.2%

Returns

ROE18.4%
ROA10.5%
ROIC (approx.)158.2%
Asset turnover0.75x

Leverage & solvency

Liabilities / assets41.1%
Debt / equity0.18x
Current ratio3.55x
Interest coverage8.31x

Cash quality & payout

Operating cash flow / net income1.74x
Accruals ratio-7.7%
Payout ratio—
Capex / revenue2.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.89B$1.71B$1.51B$1.50B$1.41B$1.32B$1.12B$1.13B
Gross profit$1.67B$1.53B$1.35B$1.36B$1.22B$1.15B$952.28M$967.26M
R&D expense$660.78M$612.28M$541.22M$615.42M$523.66M$524.90M$481.89M$542.01M
SG&A expense$593.46M$593.21M$555.10M$555.29M$529.00M$537.91M$459.29M$504.68M
Operating income$418.68M$325.05M$249.90M$185.03M$163.11M$87.89M$11.10M-$79.42M
Interest expense$42.41M$39.74M$32.89M$26.87M$16.36M$8.00M$7.00M$6.95M
Pretax income$410.36M$312.46M$259.21M$149.24M$147.16M$99.55M$20.90M-$85.35M
Income tax$25.65M$75.45M$31.86M$82.74M$22.32M$5.23M$19.63M$66.53M
Net income$384.71M$237.01M$227.36M$66.50M$124.84M$94.32M$1.27M-$151.88M
EBITDA$456.00M$363.95M$291.05M$221.02M$198.84M$117.74M$43.91M-$29.18M
EPS (basic)0.260.160.16—0.090.070.00—
EPS (diluted)0.250.160.15—0.080.060.00—
Weighted avg. shares (diluted)1.52B1.51B1.51B—1.49B1.46B1.45B—
Balance sheet
Cash & equivalents$5.78B$5.10B$4.79B$4.55B$4.04B$2.76B$2.52B$2.64B
Receivables$1.09B$1.06B$938.02M$865.08M$863.28M$770.78M$717.24M$676.28M
Inventory$807.92M$732.60M$681.59M$608.23M$531.69M$502.87M$494.66M$494.99M
Current assets$7.93B$7.22B$6.60B$6.23B$5.66B$4.31B$3.90B$3.99B
PP&E, net$1.65B$1.64B$1.64B$1.64B$1.63B$1.62B$1.60B$1.58B
Intangibles$37.92M$60.96M$61.68M$62.70M$63.58M$64.89M$50.14M$51.09M
Total assets$9.88B$9.18B$8.55B$8.19B$7.63B$6.30B$5.84B$5.92B
Current liabilities$2.23B$2.12B$1.81B$1.83B$2.37B$2.21B$1.98B$2.21B
Short-term debt$248.86M$190.90M$116.14M$57.29M$813.30M$808.39M$763.47M$851.53M
Long-term debt$825.22M$882.16M$962.51M$961.91M—$146.09M$160.16M$166.48M
Total debt$1.07B$1.07B$1.08B$1.02B—$954.49M$923.63M$1.02B
Total liabilities$4.06B$4.00B$3.79B$3.83B$3.50B$2.53B$2.34B$2.59B
Shareholders' equity$5.82B$5.17B$4.76B$4.36B$4.13B$3.77B$3.50B$3.33B
Net debt-$4.71B-$4.02B-$3.71B-$3.53B—-$1.80B-$1.59B-$1.62B
Shares outstanding1.48B1.47B1.44B1.44B1.44B1.43B1.40B1.39B
Cash flow statement
Operating cash flow$508.71M$462.82M$201.34M$417.35M$402.55M$263.60M$44.08M$75.16M
Capital expenditure$35.17M$27.48M$40.79M$37.52M$48.08M$43.83M$56.41M$92.48M
Free cash flow$473.53M$435.34M$160.55M$379.82M$354.47M$219.77M-$12.32M-$17.32M
Investing cash flow-$35.76M-$49.35M-$45.51M-$38.34M-$49.27M-$66.61M-$121.94M-$93.61M
Financing cash flow$102.19M-$6.05M$68.63M$96.93M$961.27M$35.02M-$33.78M-$4.52M
Depreciation & amortization$37.32M$38.91M$41.14M$35.98M$35.73M$29.85M$32.80M$50.25M
Stock-based compensation$132.62M$137.47M$123.36M$123.76M$140.79M$150.55M$95.48M$107.62M

Free plan shows the latest 8 periods; Pro shows all 47 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.